Product Images Eribulin Mesylate

This text provides data on a clinical trial comparing Eribulin Mesylate Injection with a control group. The trial involved 508 patients in the Eribulin group and 254 patients in the control group. The graph shows the number of patients at risk over time in months, up to 36 months.*

Not available.*

This appears to be a list of symptoms including fever, cough, chills, and burning or pain during urination. These symptoms may indicate an infection or illness and should be evaluated by a healthcare professional.*

This text mentions symptoms related to low white and red blood cell counts, such as nausea and anemia with associated symptoms like constipation, weakness, tiredness, and hair loss (alopecia). These symptoms can be indicative of various health conditions that warrant further medical evaluation and management.*

This is a list of common symptoms that an individual may experience. Symptoms include tiredness, stomach pain, nausea, fever, hair loss (alopecia), and constipation. These symptoms can indicate various health issues and it is recommended to consult a healthcare professional for a proper evaluation and treatment.*

This is a prescription information for Eribulin Mesylate Injection, a cytotoxic agent used for intravenous use in single-dose vials. It contains 1 mg/2 mL (0.5 mg/mL) of the sterile solution. The medication should not be frozen or refrigerated and should be stored at 25°C (77°F) with excursions permitted between 15°-30°C (59°-86°F). For dosage and usage guidelines, refer to the accompanying prescribing information. This product is distributed by Baxter Healthcare Corporation in Deerfield, Illinois, USA.*

Description: This text provides information on a medication called Eribulin Mesylate Injection, a cytotoxic agent for intravenous use. Each single-dose vial contains 1 mg of eribulin mesylate in 2 mL of solution. It is recommended to discard any unused portion of the vial. The dosage and usage details are available in the accompanying prescribing information. The medication is stored at room temperature with excursions permitted to a specific range. It should not be frozen or refrigerated. Manufacturer details are also provided in the text.*

This is prescription medication labeled as Eribulin Mesylate Injection, with a concentration of 1 mg/2 mg/2m for intravenous use. It is a sterile solution and a cytotoxic agent that comes in single-dose vials which should be discarded if unused. This product is distributed by Baxter Healthcare Corporation, based in Deerfield, IL, USA, and is a registered trademark of Baxter International Inc. Made in Germany.*